Accessibility Menu
Drugs Made In America Acquisition II Corp. logo

Drugs Made In America Acquisition II Corp.(NASDAQ) DMII

Market Cap$643.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+2%
5 YearN/A
1 YearN/A
1 Month+1%
$10.11
+0.05%
+0.01Today
Drugs Made In America Acquisition II Corp. last closing stock price
MetricPriceDate
Last closeUSD 10.112026-07-27
Drugs Made In America Acquisition II Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.15%USD 10.092026-07-20
1 month+0.55%USD 10.052026-06-26
3 month+0.95%USD 10.012026-04-28
Year to date+2.07%USD 9.902025-12-31
Since inception+2.23%USD 9.882025-12-03

Drugs Made In America Acquisition II Corp. Financials at a Glance

Market Cap

$643.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$8.58M

EPS (TTM)

$0.13

P/E Ratio

75.37

Dividend

$0.00

Beta (Volatility)

0.22 (Low)

Price

$10.11

Volume

149

Open

$10.10

Previous Close

$10.11

Daily Range

$10.10 - $10.11

52-Week Range

$9.86 - $10.11

Estimated Earnings Date

N/A

DMII News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. is a financial services company focused on executing business combinations, including mergers and acquisitions. Founded in 2024 and based in Fort Lauderdale, Florida, the company currently lacks significant business operations but aims to create value through strategic partnerships.

Products and Services
  • Business combination strategies including mergers and acquisitions
  • Focus on the pharmaceutical sector
  • Potential for partnerships with innovative healthcare companies
Growth Outlook
  • Market capitalization of approximately $529.87 million indicates strong investor interest
  • Recent quarterly net income of $4.34 million showcases potential profitability
  • Long-term investments exceeding $509 million provide a solid financial foundation
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio of 0.60 suggests attractive valuation
  • Quarterly net income of $4.34 million reflects effective cost management
  • Cash and cash equivalents of $347,720 indicate liquidity for future operations
Drugs Made In America Acquisition II Corp. operates in a unique niche within the financial services sector, focusing on strategic business combinations. The company's recent financial performance, including a notable net income, highlights its potential for growth and profitability. With a strong market capitalization and significant long-term investments, the company is well-positioned to explore opportunities in the pharmaceutical industry. Investors may find the company's focus on mergers and acquisitions appealing, especially given its current financial standing and strategic objectives.
AI Generated • Jul 5, 2026

Industry

Capital Markets

Sector

Financials

Employees

2

CEO

Lynn Darlene Stockwell

Headquarters

New York, NY 33301, US

DMII Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2.35%

Return on Capital

-0.27%

Return on Assets

1.68%

Earnings Yield

1.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$643.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

63.70M

Volume

149

Avg. Volume

114.08K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.37M

EBITDA

-$1.37M

Operating Cash Flow

-$1.11M

Capital Expenditure

-$4.00

Free Cash Flow

-$1.11M

Cash & ST Invst.

$347.72K

Total Debt

$450.00K

Drugs Made In America Acquisition II Corp. Performance Analysis

Drugs Made In America Acquisition II Corp. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Drugs Made In America Acquisition II Corp. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Drugs Made In America Acquisition II Corp. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.00N/A
20252025-12-31USD 0.07N/A
Drugs Made In America Acquisition II Corp. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30100.0%
Q32025-09-30N/A
Q42025-12-311100.0%
Q12026-03-31-58.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$643.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$321.69M

N/A

Employees

2

N/A

Net Income

$4.34M

+7411.7%

EBITDA

-$132.03K

-122.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$347.72K

+4873.8%

Total Debt

$450.00K

+79.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$450.00K

+79.9%

Return on Assets

1.68%

N/A

Return on Invested Capital

-0.27%

N/A

Free Cash Flow

-$102.50K

N/A

Operating Cash Flow

-$102.50K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,396.49-0.00%
^DJIDJI
$52,083.00+0.00%
^IXICNASDAQ
$24,847.16-0.01%
BTCBitcoin
$64,796.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About DMII

What is the current price of Drugs Made In America Acquisition II Corp.?

Drugs Made In America Acquisition II Corp. is trading at $10.11 per share.

What is the 52-week range for Drugs Made In America Acquisition II Corp.?

Over the past 52 weeks, Drugs Made In America Acquisition II Corp. has traded between $9.86 and $10.11.

How much debt does Drugs Made In America Acquisition II Corp. have?

As of the most recent reporting period, Drugs Made In America Acquisition II Corp. reported total debt of $450.00K.

How much cash does Drugs Made In America Acquisition II Corp. have on hand?

Drugs Made In America Acquisition II Corp. reported $347.72K in cash and cash equivalents in its most recent financial results.

What is Drugs Made In America Acquisition II Corp.’s dividend yield?

Drugs Made In America Acquisition II Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services